HAVCR1 and prostate cancer: These potential signalling pathways and further studies on inhibitors to HAVcR-1-induced cell behavioural changes and the signalling pathways activity are required to potentiate the HAVcR-1 inhibition as a treatment of prostate cancer and/or prevention of metastatic disease.